Menu Search
Equities

23andMe Holding Co.

ME:NAQ

23andMe Holding Co.

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.23
  • Today's Change0.08 / 2.54%
  • Shares traded1.00
  • 1 Year change-81.29%
  • Beta1.1720
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year 23andMe Holding Co.'s revenues fell -26.66% from 299.49m to 219.64m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 311.66m to a larger loss of 666.70m.
Gross margin46.51%
Net profit margin-318.39%
Operating margin-324.02%
Return on assets-109.86%
Return on equity-169.23%
Return on investment-142.15%
More ▼

Cash flow in USDView more

In 2024, cash reserves at 23andMe Holding Co. fell by 170.36m. Cash Flow from Financing totalled 3.58m or 1.63% of revenues. In addition the company used 164.32m for operations while cash used for investing totalled 9.63m.
Cash flow per share-23.94
Price/Cash flow per share--
Book value per share3.95
Tangible book value per share2.02
More ▼

Balance sheet in USDView more

23andMe Holding Co. appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio1.24
Quick ratio1.14
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.